Top
Relapsed or Refractory B Cell Lymphoma - Healing Genes
1366
post-template-default,single,single-post,postid-1366,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Relapsed or Refractory B Cell Lymphoma

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma


Phase 1

DESCRIPTION:

Researchers in 6 states seek lymphoma patients to trial an autologous (to the self) T-cell infusion after those cells are gene-modified to target HER2-antigen-producing tumors. The investigatory treatment gene-modifies the patient’s own immune T-cells to recognize and kill HER-2 positive tumor cells. This will require leukapheresis to collect the T-cells, which are gene-modified in the lab before being returned to the patient. Additional antibody treatments against HER2-producing tumors will also be given.

Follow up to assess the safety and effectiveness of the tumor-targeting treatment will be required for at least 24 weeks..


PATIENT MUST:

  • Be 18 to 80 years of age
  • Have histologically-confirmed relapsed or refractory CD20+ B-cell lymphoma of one of the following types, with documented disease progression or recurrence following the immediate prior therapy: DLBCL (regardless of cell of origin or underlying molecular genetics), MCL, PMBCL, Gr3b-FL, TH-FL (prior dx of FL before transforming to DLBCL)
  • Have a life expectancy of 6 months or greater
  • Not have known active central nervous system (CNS) involvement by malignancy

THE STUDY INVOLVES:

  1. Screening to confirm acceptance to the study.
  2. Leukapheresis to isolate T-cells which are then modified in the lab.
  3. The HER2-modified T cells will be given into the vein through an IV line.
  4. Rituximab antibody therapy will be infused.
  5. Follow up to assess the safety and effectiveness of the drug to reduce the tumor will be required for at least a year.

LOCATIONS & CONTACTS:
The study sites are:
Emory University, Winship Cancer Institute in Atlanta, GA, Map.
Indiana Bone and Marrow Transplantation in Indianapolis, IN, Map.
University of Minnesota in Minneapolis, MN, Map.
Ohio State University in Columbus, OH, Map.
Tennessee Oncology in Nashville, TN, Map.
The University of Texas MD Anderson Cancer Center in Houston, TX, Map.
 
Contacts:
Francis Payumo  |  530-868-6471  |  [email protected]
Patty Harris  |  [email protected]
 
SPONSORS
Unum Therapeutics Inc.
 
Or go online:
https://clinicaltrials.gov/ct2/show/NCT03189836

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader